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Abstract: Recent literature highlights the importance of identifying factors associated with mild 
cognitive impairment (MCI) and Alzheimer’s Disease (AD). Actual validated biomarkers include 
neuroimaging and cerebrospinal fluid assessments; however, we investigated non-Aβ-dependent 
factors associated with dementia in 12 MCI and 30 AD patients. Patients were assessed for global 
cognitive function (Mini-Mental state examination—MMSE), physical function (Physical 
Performance Test—PPT), exercise capacity (6-min walking test—6MWT), maximal oxygen uptake 
(VO2max), brain volume, vascular function (flow-mediated dilation—FMD), inflammatory status 
(tumor necrosis factor—α ,TNF- α, interleukin-6, -10 and -15) and neurotrophin receptors (p75NTR 
and Tropomyosin receptor kinase A -TrkA). Baseline multifactorial information was submitted to 
two separate backward stepwise regression analyses to identify the variables associated with 
cognitive and physical decline in demented patients. A multivariate regression was then applied to 
verify the stepwise regression. The results indicated that the combination of 6MWT and VO2max 
was associated with both global cognitive and physical function (MMSE = 11.384 + (0.00599 × 6MWT) 
− (0.235 × VO2max)); (PPT = 1.848 + (0.0264 × 6MWT) + (19.693 × VO2max)). These results may offer 
important information that might help to identify specific targets for therapeutic strategies (NIH 
Clinical trial identification number NCT03034746). 
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1. Introduction. 
Dementia is a common age-related disorder leading to cognitive and functional impairments [1,2], 
affecting the quality of life of patients [3]. The global prevalence is estimated to be as high as 24 million 
and is expected to increase as people live longer, doubling every 20 years, predicted to reach  
81.1 million worldwide by 2040 [1]. Older individuals can have demonstrable cognitive impairment 
without crossing the threshold for dementia and this condition has been termed “mild cognitive 
impairment” (MCI) [2]. MCI is characterized by cognitive changes that are greater than expected for 
an individual’s age and education level but do not severely interfere with daily-life activities [3]. 
Considerably important is the fact that individuals with MCI have an increased risk of developing 
Alzheimer’s disease (AD) [2,4]. AD is the most common form of dementia, characterized by a 
progressive deterioration of cognitive function due to widespread neuronal loss and synaptic 
dysfunction, accompanied by extracellular amyloidosis and intracellular tangle formation [5]. 
Current literature suggests that patients with MCI progress to AD at a rate of 10% to 15% per year, 
and 80% of these patients converted to AD after approximately 6 years of follow-up [2].  
In recent decades, much effort has been dedicated to the early clinical diagnosis of dementing 
disorders with the aim of identifying factors associated with AD [6]. Most of the studies have mainly 
focused on the association of cognitive decline with biomarkers obtained by neuroimaging and from 
cerebrospinal fluid [4,5,7,8]. However, it has been demonstrated that cognitive deterioration, 
accumulation of amyloid-β (Aβ) and tau protein are not equivalent and not linear with respect to 
disease progression and the appearance of its cognitive symptoms [9]. 
Interestingly, other recent studies provided evidence about the polyhedral etiology of AD [10–14], 
demonstrating that AD symptoms and dysfunctions are not confined to the cognitive and executive 
level, but range over several physical and bioenergetic functions [15–19]. Moreover, it has been 
demonstrated that cardiorespiratory fitness, which is closely related to the level of physical activity, 
is strongly related with the rate of cognitive decline [20,21]. These recent findings may indicate that 
some non-Aβ-dependent factors may be associated with AD. Importantly, recognizing variables that 
can be associated with MCI and AD and can be easily evaluated within the clinical setting is of 
primary importance. Moreover, the early recognition of cognitive decline would promote the 
appropriate implementation of preventive approaches.  
In light of this premise, the aim of this study was to explore the association, with a multivariate 
approach, between global cognitive function, physical function and a wide panel of non-Aβ-
dependent factors potentially associated with MCI and AD. Our working hypothesis was that, due 
to the several physiological mechanisms involved in the AD pathogenesis of the disease, non-Aβ-
dependent variables (i.e., metabolic, inflammatory, vascular, and functional biomarkers) would 
transpire to be associated with this neurodegenerative disease. 
2. Methods 
Participants. Patients with MCI with positive biomarkers for AD and patients with AD were 
recruited from the Neuromotor and Cognitive Rehabilitation Research Center of Azienda 
Ospedaliera Universitaria Integrata of Verona, and the Geriatric Institute Mons. Arrigo Mazzali 
Foundation (Mantua, Italy). Clinical diagnosis of MCI with biomarkers for AD and probable AD was 
established according to the National Institute on Aging-Alzheimer's Association diagnostic 
guideline for MCI due to AD and AD [19,22,23]. Patients with MCI with probable biomarkers for AD 
and patients with AD were screened, including health history, physical examination, blood pressure 
assessment, blood sample, level of physical activity, and familiarization with the study procedures. 
Other exclusion criteria were as follows: history of depression or psychosis, alcohol or drug abuse, 
other neurological disorders (e.g., Parkinson’s disease, traumatic brain injury, stroke, multiple 
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sclerosis), cardiac, orthopedic (e.g., osteoarthrosis) or respiratory (e.g., chronic obstructive 
pulmonary disease) conditions. All procedures were conducted after informed and written consent 
was obtained from the patients and their relatives in accordance with the Declaration of Helsinki, as 
part of a protocol approved by the Institutional Review Board of the Azienda Ospedaliera 
Universitaria Integrata (Verona, Italy—#2389; NIH Clinical trial identification number: 
NCT03034746).  
Assessment procedure and study overview. Neurologists and clinical neuropsychologists with 
specific expertise in dementia investigated the cognitive profile of the patients with a full 
neuropsychological profile and the following tests were performed: Mini-Mental State Examination 
(MMSE) was used to assess the global cognitive status; Clinical Dementia Rating (CDR) scale was 
administered to quantify the severity of dementia; the Italian version of the Frontal Assessment 
Battery (FAB) was used to assess executive functions. Kinesiologist performed physical tests. The 
Physical Performance Test (PPT) was used to assess physical function competences, while the test for 
the estimate of maximal oxygen consumption (VO2max) and 6-min walking test (6MWT) were used 
to assess bioenergetic and endurance aspects. The flow-mediated dilation (FMD) test, performed by 
an expert and skilled radiologist, was used for assessing the vascular function, while an MRI 
examination was performed to derive brain volume measures. Patients with MCI and AD included 
in this study underwent three testing sessions on three different days. On the first day, participants 
were evaluated for cognitive profile and underwent a blood sample. On the second day, participants 
performed PPT, 6MWT, and VO2max tests, while on the third day, participants underwent an FMD 
test and MRI.  
Level of physical activity. The International Physical Activity Questionnaire (IPAQ) was used to 
estimate the level of physical activity of the participants. Each question was administered to patients 
and their caregivers. 
Blood sample and analysis. Venous peripheral blood (25 mL) was collected between 9:00 and 10:00 
am in a fasted state and processed within 2 h to separate monocytes (Mono). From a different 
vacutainer, plasma was separated from peripheral blood by centrifugation (1200 rpm for 20 min at 4 
°C) and kept at −80 °C until analysis. By Fluorescence Activated Cell Scanning (FACS) Scan analysis, 
Tropomyosin receptor kinase A -TrKA and p75 neurotrophins -p75NTR- receptor expression 
(expressed as % of positive cells and Mean Fluorescent Intensity: MFI) and interleukin (IL) 6 and 10 
were evaluated on monocytes. More details of the methods are given in our previous paper. Plasmatic 
NGF concentration was measured by enzyme immunoassay ELISA (DuoSet ELISA development 
R&D System, #DY256-05) according to the manufacturer’s protocol [24]. Plasmatic VEGF and TNF 
concentrations were measured by enzyme immunoassay ELISA (DuoSet ELISA development R&D 
System, VEGF Human ELISA Kit #DY256-0 Invitrogen # KHG0111 and TNF alpha Human ELISA Kit 
Invitrogen #BMS223-4) [24]. The plasmatic concentration of IL-15 was measured by enzyme 
immunoassay ELISA (RAYBIOTECH) according to the manufacturer’s protocol [24]. We decided to 
perform some measures on peripheral monocytes and some on plasma since the former are 
recognized to have a pivotal role in the pathogenesis of AD, while the latter is a non-neurological 
sample that is useful for the evaluation of peripheral biomarkers of AD [24].  
Physical performance test (PPT). The nine-item PPT assesses physical function competences. The 
following maneuvers simulating daily activities were assessed: writing a sentence; simulation of 
eating; rising up and putting a heavy book on a shelf; dressing and taking off a jacket; picking up a 
coin from the floor; turning 360°; gait test; climbing stairs; number of stairs climbed. Seven of the nine 
tasks were timed and the time interval scores of each task were given, from 0 if the task was unable 
to be performed to 4 if it was performed as well as it could be. During the 360° turn, stability and 
continuity of turning were assessed. The maximum score for the nine items was 36 points [25].  
Maximal oxygen consumption (VO2max). Before performing the VO2max test, participants were 
instructed to find the self-selected speed (SSS, the most comfortable speed) on the treadmill. The test 
started from 0.5 km/h and the speed was increased by 0.1 km/h every 30 s until the patients referred 
to walk comfortably [26]. Subsequently, after a 15-min break, subjects performed a 3-speed walking 
test on a treadmill (Run Race, Technogym, Gambettola, Italy). A portable metabolimeter (K4b2, 
J. Clin. Med. 2019, 8, 224 4 of 12 
 
Cosmed, Rome, Italy) was used for cardiopulmonary measures. The test consisted of 2 phases: in the 
first phase, the subjects were asked to stand in the resting condition for 2 min while the resting oxygen 
uptake and heart rate (HR) were recorded. The second phase consisted of three 5-min bouts of 
walking at 80%, 100% and 120% of SSS. The initial minutes of walking secured a steady state VO2. 
For any bout, the average of the last minute VO2 measurements, and HR were calculated. After 
having defined the HR/VO2 relation using the linear regression, VO2max was than calculated by 
means of the following formula:  
VO max	 = (HRmax – q)/m  
where HRmax = theoretical HR max calculated using Karvonen formula (220-age); q = intercepts; m 
= angular coefficient.  
Six-minute walking test (6MWT). The 6MWT measures the maximum distance that a person can 
walk over 6 min and it is commonly used as an assessment of exercise capacity. The participants were 
instructed to walk from one end of a 15-meter course to the other and back again as many times as 
possible in 6 min, while under the supervision of a kinesiologist. After each minute, participants were 
informed of the time elapsed and were given standardized encouragement. The distance (meters) 
covered in 6 min was recorded [27].  
Flow-mediated dilation (FMD). The FMD test was performed in a quiet room with participants in 
abstinence from alcohol, antioxidants (i.e., orange juice, beetroot juice) and caffeine for at least 12 h 
[28]. High-resolution ultrasound was used to image the brachial artery at rest and after 5 min of 
ischemia. All the FMD tests were performed with the participant in the supine position, with the right 
arm extended at an angle of ~90° from the torso. The brachial artery was imaged using a high-
resolution ultrasound system Logiq-7 ultrasound Doppler system (General Electric Medical Systems, 
Milwaukee, WI, USA). The ultrasound Doppler system was equipped with a 12–14 MHz linear array 
transducer. The brachial artery was imaged 5–10 cm above the antecubital fossa in the longitudinal 
plan, and the diameter was determined at 90° angle along the central axis of the scanned area. When 
an optimal image was acquired, the position was maintained for the whole test and all scans were 
stored for later analyses. After baseline brachial artery imaging, a blood pressure cuff was placed 
around the forearm and inflated to 250 mmHg for 5 min. Brachial artery images and blood velocity 
were obtained continuously 30 s before and 2 min after cuff release [28]. The brachial artery images 
were analyzed by a blinded investigator by means of FloWave.US [29]. Arterial diameter was 
measured as the distance (mm) between the intima-lumen interfaces for the anterior and posteriors 
walls. Utilizing arterial diameter and the blood velocity, blood flow (BF) was calculated as follows:  
BF (mL/min) = blood velocity · ᴨ · (vessel diameter/2)2 · 60  
The calculation of FMD as a percentage change uses the peak diameter in response to reactive 
hyperemia in relation to the baseline diameter and was calculated using the following equation: 
FMD (%) = (peak diameter-baseline diameter)/baseline diameter  
and when multiplied by 100, FMD is expressed as a percentage of change in the vessel caliber [28].  
The post cuff release shear rate was calculated using the following equation: Shear rate (s−1) = 8 
Vmean/vessel diameter. The cumulative shear rate (s−1 · s) and the reactive post cuff release (total blood 
flow over 2 min) were integrated using the trapezoidal rule and calculated as: 
 
 [yi x(i+1) − xi  +  
1
2     y(i+1) − yi   x(i+1) − xi ]  
Consequently, FMD was normalized to the shear rate (FMD/Shear Rate) [28]. 
Brain volume. All patients were scanned on a 3T Philips Achieva MRI system equipped with an 
8-channel head coil. Subjects were instructed to remain as still as possible during scanning to reduce 
motion artefacts in the collected images. A 3D T1-weighted turbo ﬁeld echo anatomical scan was 
acquired in all subjects (TR/TE = 8.16/3.73 ms; 180 slices, 1 × 1 × 1 mm3). Brain tissue volume, both 
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non-normalised and normalised for subject head size, was estimated with SIENAX [30,31], as 
included in FSL 5.0.9. SIENAX starts by extracting brain and skull images from the single whole-head 
input data. The brain image is then affine-registered to the MNI152 space template and tissue-type 
segmentation with partial volume estimation is carried out in order to calculate the total volume of 
brain tissue (TBV). This parameter of interest was obtained as the sum of measured cortical and 
subcortical gray matter (GM) and white matter (WM) volumes, including the brainstem and 
cerebellum [32]. 
Statistical analysis. Data are presented as mean ± SD. First, normality was assessed by the 
Shapiro–Wilk test. The Pearson correlation coefficients between both MMSE/PPT and all the 
measured variables were calculated. Predictive analyses were performed considering the variables 
correlated with MMSE and PPT (P-to enter = 0.1). Two separated backward stepwise regression 
analyses were conducted for the selected variables to identify the most predictable variables. Finally, 
a multivariate regression (enter method) was used to verify the stepwise regression analyses and 
obtain the final equation. In the final resultant model, the significance was set at p = 0.05. All statistical 
analyses were performed with SigmaPLOT Windows Version 14.0 (Systat Software, Chicago, IL, 
USA). 
3. Results 
Subjects’ characteristics. The demographic and clinical characteristics of the study participants are 
displayed in Table 1. Forty-two individuals (MCI with positive biomarkers for AD:12, AD:30) were 
included in this study. Drugs for AD and other medications taken by the patients with MCI and AD 
are also displayed in Table 1. The data concerning all the assessed variables are displayed in Table 2.  
Table 1. Demographic and clinical characteristic of the study participants. 
Characteristic M ± SD 
MCI, n(%) 12 (28.6) 
AD, n (%) 30 (71.4) 
Female, n(%) 27 (64.3) 
Age, years 78.7 ± 5.7 
Weight, kg 72.5 ± 14.5 
Height, m 1.64 ± 0.2 
IPAQ (METs·min·week−1) 3837 ± 589 
Clinical Characteristics  
Time since diagnoses, years 4.5 ± 2.5 
MMSE, (0–30) 24 ± 2.9 
CDR, (0–3) 1.25 
FAB, (0–18) 9.5 ± 3 
IADL, (0–100%) 61.7 ± 32.5 
Health-Related Markers  
Sys, mmHg 130.4 ± 6.2 
Dia, mmHg 87.8 ± 5.2 
HCT, L/L 0.42 ± 0.04 
Hb, g/L 13.6 ± 1.4 
Glicemia, mg/dL 100.5 ± 26.2 
HDL, mg/dL 61.9 ± 23.7 
LDL, mg/dL 110 ± 23 
Trigl, mg/dL 102.7 ± 29.4 
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Cortisol, nmol/L 14.5 ± 3.4 
Pharmacological Treatment, n (%)  
Cholinesterase inhibitors 14(33.3) 
Antipsychotics 4(9.5) 
Antidepressants 7(16.6) 
Benzodiazepines  2(4.8) 
Comorbidities, n (%)  
Cardiovascular disease 9(21.4) 
Diabetes 3(7.1) 
Arthrosis 5(11.9) 
Note. MCI, Mild Cognitive Impairment; AD, Alzheimer’s Disease; IPAQ, international physical 
activity questionnaire; MMSE, Mini Mental State Examination; CDR, Clinical Dementia Rating Scale; 
FAB, Frontal Assessment Battery; IADL, independent activities of daily living; Sys and Dia, systolic 
and diastolic blood pressure; HCT, hematocrit; Hb, hemoglobin; HDL, high-density lipoprotein; LDL 
low-density lipoprotein; Trigl, triglycerides. Values are expressed as mean ± standard deviation (or 
percentage in parentheses). 
Table 2. Assessed variables of patients with MCI with positive markers for AD and patients with AD. 
Markers M ± SD 
Bain volume   
Non normalized, mL 928 ± 119 
Normalized for skull size, mL 1354 ± 75 
Physical and bioenergetic variables  
6MWT, m 365 ± 87 
VO2max, mL·kg·min−1 25.8 ± 5.9 
Vascular function and inflammatory markers  
VEGF, pg/mL 31.9 ± 10.5 
TNF-a, pg/mL 0.714 ± 0.015 
IL-15, pg/mL 29.1 ± 23.1 
FMD, % 7.8 ± 2.6 
FMD/Shear 0.1015 ± 0.149 
Shear Rate 175,618 ± 111,627 
Lymphocytes markers and receptors  
β-NGF, pg/mL 103.9 ± 51.8 
TrkA Mono, % 93.7 ± 7.3 
p75 Mono, % 81.4 ± 9.4 
MFI TrkA 153.6 ± 101.7 
MFI p75 23.9 ± 10.7 
IL-6, % 6.5 ± 2.1 
IL-10, % 4.4 ± 2.4 
Note. MCI, Mild Cognitive Impairment; AD, Alzheimer’s Disease; MMSE, Mini Mental State 
Examination; PPT, physical performance test; 6MWT, 6-min walking test; VO2max, maximal oxygen 
uptake; VEGF, vascular endothelial growth factor; TNF-α, tumor necrosis factor-α; IL-15, interleukin-
15; β-NGF, β-nerve growth factor; TrkA, tropomyosin-related kinase receptor; p75, p75receptor; 
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Mono, monocytes; PBMC, peripheral blood mononuclear cells; MFI: mean fluorescence level. Values 
are expressed as mean ± standard deviation. 
Correlations between global cognitive function, physical function and non-Aβ-dependent variables. The 
analysis of correlations by means of the Pearson correlation coefficient showed significant 
correlations between MMSE and IADL (p < 0.001), 6MWT (p < 0.001), VO2max (p < 0.001), β-NGF (p = 
0.004), HCT (p = 0.015), TrkA Mono (p = 0.020), and MFIp75NTR (p = 0.020). The same analysis 
revealed significant correlations between PPT and IADL (p < 0.001), 6MWT (p < 0.001), VO2max (p = 
0.004), β-NGF (p = 0.015), MFIp75NTR (p < 0.001), and IL-10 (p = 0.016) (Table 3).  
Table 3. Pearson correlation coefficients between MMSE, PPT and all measured variables. 
Variables 
MMSE PPT 
p R p R 
MMSE ----- ----- ----- ----- 
PPT ----- ----- ----- ----- 
Age 0.331 0.198 0.298 0.201 
Gender 0.276 0.159 0.300 0.299 
Weight 0.199 0.174 0.250 0.183 
Non-correted Brain Volume 0.194 0.023 0.168 0.037 
Corrected Brain Volume 0.202 0.129 0.198 0.248 
IADL <0.001 0.664 <0.001 0.725 
6MWT <0.001 0.627 <0.001 0.749 
VO2max <0.001 0.662 <0.001 0.490 
VEGF 0.789 0.178 0.876 0.112 
TNF-a 0.179 0.292 0.098 0.209 
IL-15 0.173 0.341 0.181 0.139 
FMD% 0.069 0.298 0.129 0.298 
FMD/Shear 0.321 0.210 0.183 0.372 
Shear Rate 0.199 0.203 0.193 0.389 
β-NGF 0.004 0.453 0.015 0.398 
TrkA Mono 0.062 0.302 0.752 0.412 
p75 Mono 0.113 0.267 0.018 0.387 
MFI TrkA 0.158 0.307 0.083 0.288 
MFI p75 0.020 0.372 <0.001 0.497 
IL-6 0.210 0.111 0.191 0.234 
IL-10 0.157 0.320 0.016 0.499 
Note. MMSE, mini mental state examination; PPT, physical performance test; 6MWT, 6-min walking 
test; VO2max, maximal oxygen uptake; VEGF, vascular endothelial growth factor; TNF-α, tumor 
necrosis factor-α; FMD, flow-mediated dilation; β-NGF, β-nerve growth factor; TrkA, tropomyosin-
related kinase receptor; p75, p75 receptor, Mono, monocytes; PBMC, peripheral blood mononuclear 
cells; MFI, mean fluorescence level. ns, non statistically significant 
Multivariate approach. Tables 4 and 5 display the results of the two separate backward stepwise 
regression analyses followed by a multivariate regression conducted to determine the linear 
relationship between non-Aβ-dependent variables and MMSE and PPT. The final result showed that 
only 6MWT (p = 0.029) and VO2max (p = 0.087) were kept in the regression by the analysis for the 
prediction of MMSE (Table 4) and PPT, 6MWT (p < 0.001) and VO2max (p = 0.079) (Table 5).  
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Table 4. MMSE multiple regression model. 
Variable Coeff. S Coeff. SE P 
Costant 13.384  2.864  
6MWT 0.00599 0.131 0.00863 0.029 
VO2max 0.235 0.341 0.130 0.087 
MMSE = 11.384 + (0.00599 × 6MWT) + (0.235 × VO2max) 
Note. Coeff., coefficient; S Coeff., standard coefficient; SE, standard error, P, p-value; 6MWT, 6-min 
walking test, VO2max, maximal oxygen uptake 
Table 5. PPT multiple regression model. 
Variable Coeff. S Coeff. SE P 
Constant 1.848  4.502  
6MWT 0.0264 0.698 0.00491 <0.001 
VO2max 19.693 0.251 10.197 0.079 
PPT = 1.848 + (0.0264 × 6MWT) + (19.693 × VO2max) 
Note. Coeff., coefficient; S Coeff., standard coefficient; SE, standard error, P, p-value; 6MWT, 6-min 
walking test; VO2max, maximal oxygen uptake. 
4. Discussion 
Although the early recognition of biomarkers potentially associated with MCI and AD is a major 
target of clinical and pre-clinical research, not a single assessment-battery has been adopted as 
standard clinical care. In the present study, we explored the association between global cognitive 
function, physical function and several non-Aβ-dependent factors potentially associated with MCI 
and AD, easily quantifiable within several clinical settings. In accordance with our hypothesis, global 
cognitive function and physical function, measured by MMSE and PPT, were associated with 6MWT 
and VO2max. It is important to note that although VO2max was kept in the two final models, it was 
only marginally significant. Importantly, the 6MWT was the factor most related with both global 
cognitive function and physical function in MCI and AD. 
Global cognitive function and physical function and their predictors. The statistical approach used to 
identify the relation between the measured variables and the global cognitive function in demented 
individuals highlighted a positive relation between exercise capacity and aerobic capacity (Table 4). 
This result suggests that dementia is a process which includes other pathways beyond Aβ deposition. 
In previous studies, exercise capacity has been shown to be strictly associated with gray matter 
volumes, as well as with memory and processing function [27,33]. Makizako and colleagues [27] 
recruited 91 community-dwelling older adults with MCI who completed a 6MWT and underwent a 
structural MRI scanning, as well as memory tests. With this study, the authors provided evidence 
about the positive relation between exercise capacity and memory function, and both variables were 
related to the gray matter volume. Furthermore, Welmer and colleagues [33] provided further 
evidence about the relation between walking speed and its association with processing speed and 
executive function in demented and non-demented elderly individuals. In demented people, 
cognitive dysfunction is often accompanied by a reduction of functional performances [17,30,34]. 
Moreover, other recent studies have highlighted the correlation between brain integrity and aerobic 
capacity in non-demented and demented people. Burns and colleagues [20] demonstrated that 
aerobic capacity was strictly related with brain atrophy in the earliest clinical stage of AD. In that 
study, the authors showed that a higher fitness level in early stage AD participants was associated 
with preserved brain volume independent of age and dementia severity. Perea and colleagues [21] 
also demonstrated that aerobic capacity is associated with increased white matter integrity in the 
early stage of AD, supporting our results. 
Consequently, we explored the relationship between non-Aβ-dependent variables and physical 
function to find variables related with functional performance. Like MMSE, the result of our 
multivariate approach generated two variables, specifically, 6MWT and VO2max (Table 5). Although 
J. Clin. Med. 2019, 8, 224 9 of 12 
 
some studies have provided evidence about the correlation between 6MWT and aerobic capacity with 
the severity of dementia, to our knowledge no studies have investigated the relation between those 
variables and PPT in MCI and AD. Bronas and colleagues [31] investigated the association between 
aerobic capacity tested by means of a direct test, the 6MWT, and a physical performance test in 
individuals with AD. The authors identified a significant correlation between all these variables, 
indicating that the 6MWT was related to physical performance in this clinical population, supporting 
the results of our study.  
Exercise as a potential strategy for counteracting the development of dementia. Interestingly, data from 
the current study suggest that the variable most associated with cognitive and functional impairment 
was exercise capacity, in this context measured by the 6MWT. Greater exercise capacity reflects 
higher levels of physical activity as well as a higher aerobic fitness level [27]. As we mentioned 
previously, all of these parameters have been associated with maintenance of cognitive function and 
decreased risk of developing dementia [27,35], suggesting that maintaining or increasing levels of 
physical activity might be a useful strategy to counteract the deleterious effects of this 
neurodegenerative disease [36–38]. Boots and colleagues [39] recently reported that a higher exercise 
capacity level is associated with better brain health and cognition, as well as with the preservation of 
critical brain areas, reduced brain atrophy, and preserved white matter microstructure in several 
populations including both cognitively healthy older adults and demented individuals. The same 
evidence has been previously reported by other authors. Bronas and colleagues [31] provided 
evidence that exercise capacity is associated with improved or maintained brain structure and 
cognitive function; Loprinzi and colleagues [40] reported that maintaining a good exercise capacity 
helps in maintaining cognitive and memory functions in demented individuals. More in detail, 
Makizako and colleagues [27] demonstrated that higher exercise capacity in individuals with MCI is 
accompanied by greater brain volume in specific brain areas such as left middle temporal gyrus, 
middle occipital gyrus, and hippocampus. Interestingly, the role of exercise capacity in brain health 
seems to be mediated by the upregulation of some neurotrophic factors such as brain-derived 
neurotrophic factor (BDNF), which appears to be highly concentrated in the hippocampus. 
Additionally, it has an important role in the synaptic plasticity, exerting its effect on synaptic structure 
and function, neurogenesis, neural survival and disease resistance [13,21,27].  
Limitations. A clear limitation of the current study was the number of patients that may indicate 
that the patients included in this study were potentially a specific sub-group of patients with MCI 
and positive biomarkers for AD and patients with AD. Also, the large number of variables probably 
were not proportioned for the number of subjects, limiting the interpretation of the results.  
Practical implications and conclusions. The statistical approach that we applied identified an 
association between exercise capacity and global cognitive and physical function in MCI and AD. 
The importance of this result is in the applicability of the assessment methods that are easy to 
implement in a standard clinical setting. Indeed, it requires a 6MWT, which can be performed in any 
quiet place, and a submaximal VO2max test. Concluding, this model could have important uses, such 
as targeting individuals for treatment as early as possible and preventative strategies in high-risk 
population groups. This result offers important information that might help in developing new and 
more effective exercise-based therapeutic strategies to counteract neurodegenerative processes.  
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